In a Significant Late-Stage Trial, Moderna's Influenza Vaccine Surpasses Commercially Available Options

In a Significant Late-Stage Trial, Moderna’s Influenza Vaccine Surpasses Commercially Available Options

In a Significant Late-Stage Trial, Moderna's Influenza Vaccine Surpasses Commercially Available Options